QSC301813

QSC301813 is a Quotient Sciences trial protocol code representing an undisclosed drug candidate developed by Carmot Therapeutics (which was acquired by Roche in 2024). The code is associated with a Phase I clinical trial (ISRCTN90651766) conducted in healthy volunteers in the United Kingdom, designed as a relative bioavailability study. Due to the high commercial sensitivity of the study, the sponsor deferred publication of the full protocol, intervention details, and endpoints. Carmot's clinical pipeline primarily focuses on incretin-based therapies for metabolic diseases like obesity and type 2 diabetes, including CT-388, CT-868, and CT-996, but the exact identity of the compound evaluated under QSC301813 remains undisclosed.